VC

Vivo Capital

www.vivocapital.com link_icon

Company Research Report: Vivo Capital, LLC



Company Overview



  • Name: Vivo Capital, LLC

  • Mission: Vivo is a global healthcare investment platform focused on fostering innovation and growth in healthcare markets through its unique Ecosystem Strategy.

  • Founded: No information is available.

  • Founders: No information is available.

  • Key People: No information is available.

  • Headquarters: Vivo Capital, LLC, 192 Lytton Avenue, Palo Alto, CA 94301

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • Known For: Vivo Capital is recognized for its multi-strategy investment platform covering venture capital, private equity, and public equity strategies targeted at the global healthcare industry.


Products



  • Products Offered: No direct products are offered as Vivo Capital primarily deals with investment strategies in various healthcare companies and does not produce tangible consumer products.

  • Product Description: Vivo engages in venture capital, private equity, and public equity investments, aiming to catalyze innovation and growth in healthcare.

  • Key Features:

  • Venture Capital: Focuses on funding venture stage companies with transformative healthcare technologies.

  • Private Equity: Aids in operational and commercial scaling of companies with growth prospects through capital provision.

  • Public Equity: Invests in global public equities in small and mid-cap biotechnology, pharmaceutical, healthcare, and life sciences firms.


Recent Developments



  • Latest Transactions and Approvals:

  • Zenas BioPharma announced pricing for an upsized Initial Public Offering (September 12, 2024).

  • Instil Bio entered into a licensing agreement with ImmuneOnco for two antibodies (August 1, 2024).

  • Verona Pharma received FDA approval for Ohtuvayre™ for COPD treatment (June 26, 2024).

  • Ronovo Surgical raised $44M in Series B financing for its surgical robotics platform (June 14, 2024).

  • Geron Corporation received FDA approval for RYTELO™ (June 6, 2024).


  • New Products / Features: No information is available on new products launched specifically by Vivo Capital.


  • Partnerships: Vivo Capital's investment strategy may involve facilitating partnerships through its ecosystem; specific partnership details are not available.


This report provides a comprehensive overview of Vivo Capital, highlighting the company's investment focus, recent developments in associated portfolio companies, and strategic approaches.